Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Rafee Talukder"'
Autor:
Namrata Singh, Maria E Suarez-Almazor, Iman Osman, Jeffrey Weber, Adi Diab, Petros Grivas, Noha Abdel-Wahab, Ala Abudayyeh, Huifang Lu, Osama Rahma, Daniel H Johnson, Chrystia M Zobniw, Van A Trinh, Juhee Song, Jeffrey A Sparks, Sabina Sandigursky, Maya Dimitrova, May Daher, Maryam Buni, Kaysia Ludford, Faisal Fa'ak, Sarah H Chung, Uma Thanarajasingam, Adewunmi Falohun, Muhammad Osama Awiwi, Nourel Hoda Tahon, Khaled M Elsayes, Emma J Montazari, Julia Chernis, Osama Abu-Shawer, Ashley M Zeman, Rafee Talukder, Jean H Tayar
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 6 (2023)
Background Management of immune-related adverse events (irAEs) is important as they cause treatment interruption or discontinuation, more often seen with combination immune checkpoint inhibitor (ICI) therapy. Here, we retrospectively evaluated the sa
Externí odkaz:
https://doaj.org/article/a43e4d1fdb674d64bed3cf237bf2c36f
Autor:
Yujie Chen, Rafee Talukder, Brian Y. Merritt, Katherine Y. King, Marek Kimmel, Gustavo Rivero, Romina Sosa
Publikováno v:
BMC Medical Genomics, Vol 14, Iss 1, Pp 1-6 (2021)
Abstract Background We report a patient with Essential Thrombocythemia (ET), subsequently diagnosed with concurrent myeloid and lymphoid leukemia. Generally, the molecular mechanisms underlying leukemic transformation of Philadelphia-negative myelopr
Externí odkaz:
https://doaj.org/article/f220d1d6f8a44aac96f4d1417927c513
Autor:
Dimitrios Makrakis, Dimitra Rafailia Bakaloudi, Rafee Talukder, Genevieve Ihsiu Lin, Leonidas N. Diamantopoulos, Tanya Jindal, Naomi Vather-Wu, Yousef Zakharia, Nishita Tripathi, Neeraj Agarwal, Scott Dawsey, Shilpa Gupta, Eric Lu, Alexandra Drakaki, Sandy Liu, Roubini Zakopoulou, Aristotelis Bamias, Claudia-Maria Fulgenzi, Alessio Cortellini, David Pinato, Pedro Barata, Petros Grivas, Ali Raza Khaki, Vadim S. Koshkin
Publikováno v:
Clinical Genitourinary Cancer. 21:286-294
To examine patient and disease characteristics, toxicity, and clinical outcomes for patients with advanced urothelial carcinoma (aUC) who are rechallenged with immune checkpoint inhibitor (ICI)-based therapy.In this retrospective cohort, we included
Autor:
Dimitrios Makrakis, Rafee Talukder, Genevieve Ihsiu Lin, Leonidas N. Diamantopoulos, Scott Dawsey, Shilpa Gupta, Lucia Carril-Ajuria, Daniel Castellano, Ivan de Kouchkovsky, Vadim S. Koshkin, Joseph J. Park, Ajjai Alva, Mehmet A. Bilen, Tyler F. Stewart, Rana R. McKay, Nishita Tripathi, Neeraj Agarwal, Naomi Vather-Wu, Yousef Zakharia, Rafael Morales-Barrera, Michael E. Devitt, Alessio Cortellini, Claudia Angela Maria Fulgenzi, David J. Pinato, Ariel Nelson, Christopher J. Hoimes, Kavita Gupta, Benjamin A. Gartrell, Alex Sankin, Abhishek Tripathi, Roubini Zakopoulou, Aristotelis Bamias, Jure Murgic, Ana Fröbe, Alejo Rodriguez-Vida, Alexandra Drakaki, Sandy Liu, Eric Lu, Vivek Kumar, Giuseppe Di Lorenzo, Monika Joshi, Pedro Isaacsson-Velho, Lucia Alonso Buznego, Ignacio Duran, Marcus Moses, Albert Jang, Pedro Barata, Guru Sonpavde, Evan Y. Yu, Robert Bruce Montgomery, Petros Grivas, Ali Raza Khaki
Publikováno v:
Clin Genitourin Cancer
Clinical genitourinary cancer, vol 20, iss 5
Clinical genitourinary cancer, vol 20, iss 5
Immune checkpoint inhibitors are a well-established treatment option for advanced urothelial carcinoma, and biomarkers of response are needed for better patient selection. We show that metastatic disease confined to lymph nodes is associated with bet
Autor:
Jonathan L. Wright, Alexander Sankin, Petros Grivas, Ignacio Duran, Ali Raza Khaki, Dimitrios Makrakis, Pedro C. Barata, Guru Sonpavde, Benjamin A. Gartrell, Vadim S. Koshkin, Evan Shreck, Lucia Carril-Ajuria, David J. Pinato, Mehmet Asim Bilen, Neeraj Agarwal, Mark P. Lythgoe, Giuseppe Di Lorenzo, Jayanshu Jain, Daniel Castellano, Ivan de Kouchkovsky, Rana R. McKay, Jure Murgic, Tyler F. Stewart, Michael Edward Devitt, Rafee Talukder, Pedro Isaacsson-Velho, Sandy T. Liu, Rafael Morales-Barrera, Lucia Alonso Buznego, Marcus Marie Moses, Leonidas Nikolaos Diamantopoulos, Aristotelis Bamias, Joseph J. Park, Ana Fröbe, Vivek Kumar, Alexandra Drakaki, Yousef Zakharia, Ariel Ann Nelson, Roubini Zakopoulou, Victor Sacristan Santos, Monika Joshi, Evan Y. Yu, Alejo Rodriguez-Vida, Michael Grant, Ajjai Alva, Christopher J. Hoimes, Abhishek Tripathi
Publikováno v:
BJU international, vol 130, iss 5
BJU Int
BJU Int
OBJECTIVES: To compare clinical outcomes with programmed-death ligand-1 immune checkpoint inhibitors (ICIs) in patients with advanced urothelial carcinoma (aUC) who have vs have not undergone radical surgery (RS) or radiation therapy (RT) prior to de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e64617a8b9d10e6092cd0be747466efd
https://escholarship.org/uc/item/8678m8j9
https://escholarship.org/uc/item/8678m8j9
Autor:
Rafee Talukder, Dimitrios Makrakis, Genevieve Ihsiu Lin, Leonidas N. Diamantopoulos, Scott Dawsey, Shilpa Gupta, Lucia Carril-Ajuria, Daniel Castellano, Ivan de Kouchkovsky, Tanya Jindal, Vadim S. Koshkin, Joseph J. Park, Ajjai Alva, Mehmet A. Bilen, Tyler F. Stewart, Rana R. McKay, Nishita Tripathi, Neeraj Agarwal, Naomi Vather-Wu, Yousef Zakharia, Rafael Morales-Barrera, Michael E. Devitt, Alessio Cortellini, Claudia Angela Maria Fulgenzi, David J. Pinato, Ariel Nelson, Christopher J. Hoimes, Kavita Gupta, Benjamin A. Gartrell, Alex Sankin, Abhishek Tripathi, Roubini Zakopoulou, Aristotelis Bamias, Jure Murgic, Ana Fröbe, Alejo Rodriguez-Vida, Alexandra Drakaki, Sandy Liu, Eric Lu, Vivek Kumar, Giuseppe Di Lorenzo, Monika Joshi, Pedro Isaacsson-Velho, Lucia Alonso Buznego, Ignacio Duran, Marcus Moses, Pedro Barata, Guru Sonpavde, Jonathan L. Wright, Evan Y. Yu, Robert Bruce Montgomery, Andrew C. Hsieh, Petros Grivas, Ali Raza Khaki
Publikováno v:
Clin Genitourin Cancer
Clinical genitourinary cancer, vol 20, iss 6
Clinical genitourinary cancer, vol 20, iss 6
Immune checkpoint inhibitors improve overall survival in advanced urothelial carcinoma, but response rates remain modest. We performed a multi-institutional retrospective cohort study comparing outcomes (observed response rate, progression-free, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::838aa9eb8a9455bbff00b10cd1e01eda
https://europepmc.org/articles/PMC10233855/
https://europepmc.org/articles/PMC10233855/
Autor:
Rafee Talukder, Dimitrios Makrakis, Leonidas N. Diamantopoulos, Lucia Carril-Ajuria, Daniel Castellano, Ivan De Kouchkovsky, Vadim S. Koshkin, Joseph J. Park, Ajjai Alva, Mehmet A. Bilen, Tyler F. Stewart, Rana R. McKay, Victor S. Santos, Neeraj Agarwal, Jayanshu Jain, Yousef Zakharia, Rafael Morales-Barrera, Michael E. Devitt, Michael Grant, Mark P. Lythgoe, David J. Pinato, Ariel Nelson, Christopher J. Hoimes, Evan Shreck, Benjamin A. Gartrell, Alex Sankin, Abhishek Tripathi, Roubini Zakopoulou, Aristotelis Bamias, Jure Murgic, Ana Fröbe, Alejo Rodriguez-Vida, Alexandra Drakaki, Sandy Liu, Vivek Kumar, Giuseppe Di Lorenzo, Monika Joshi, Pedro Isaacsson Velho, Lucia Alonso Buznego, Ignacio Duran, Marcus Moses, Pedro Barata, Guru Sonpavde, Evan Y. Yu, Jonathan L. Wright, Petros Grivas, Ali Raza Khaki
Publikováno v:
Clinical genitourinary cancer, vol 20, iss 2
Clin Genitourin Cancer
Clin Genitourin Cancer
Background: Immune checkpoint inhibitors (ICI) improve overall survival (OS) in patients with locally advanced, unresectable, or metastatic urothelial carcinoma (aUC), but response rates can be modest. We compared outcomes between patients with and w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e77cc9c27e1a3725c9bb47e228d859c
https://escholarship.org/uc/item/9mh6t47q
https://escholarship.org/uc/item/9mh6t47q
Autor:
Rafee Talukder, Dimitra Rafailia Bakaloudi, Dimitrios Makrakis, Nishita Tripathi, Neeraj Agarwal, Tanya Jindal, Vadim S Koshkin, Jeffrey Johnson, Yousef Zakharia, Jason Brown, Macarena Rey-Cárdenas, Daniel Castellano, Ajjai Shivaram Alva, Roubini Zakopoulou, James Korolewicz, Alexandra Drakaki, Pedro C. Barata, Petros Grivas, Ali Raza Khaki
Publikováno v:
Journal of Clinical Oncology. 41:478-478
478 Background: Erdafitinib is FDA-approved for patients (pts) with advanced urothelial carcinoma (aUC) with FGFR2/3 mutation or fusion and progression after platinum-based chemotherapy. It is postulated that FGFR3-altered aUC may be a “cold tumor
Autor:
Dimitra Rafailia Bakaloudi, Rafee Talukder, Dimitrios Makrakis, Neeraj Agarwal, Nishita Tripathi, Aristotelis Bamias, Roubini Zakopoulou, Jason Brown, James Korolewicz, Claudia A.M. Fulgenzi, Tanya Jindal, Jure Murgic, Ana Fröbe, Jeffrey Johnson, Alexandra Drakaki, Alejo Rodríguez-Vida, Macarena Rey-Cárdenas, Lucia Andrea Alonso Buznego, Ali Raza Khaki, Petros Grivas
Publikováno v:
Journal of Clinical Oncology. 41:472-472
472 Background: PBC followed by avelumab switch maintenance in non-progressors is the standard first line (1L) aUC treatment. We describe clinical features and outcomes in a ‘real-world’ cohort treated with avelumab maintenance for aUC. We hypoth
Autor:
Vadim S. Koshkin, Nicholas Henderson, Marihella James, Divya Natesan, Dory Freeman, Amanda Nizam, Christopher T. Su, Ali Raza Khaki, Chelsea K. Osterman, Michael J. Glover, Ryan Chiang, Dimitrios Makrakis, Rafee Talukder, Emily Lemke, T. Anders Olsen, Jayanshu Jain, Albert Jang, Alicia Ali, Tanya Jindal, Jonathan Chou, Terence W. Friedlander, Christopher Hoimes, Arnab Basu, Yousef Zakharia, Pedro C. Barata, Mehmet A. Bilen, Hamid Emamekhoo, Nancy B. Davis, Sumit A. Shah, Matthew I. Milowsky, Shilpa Gupta, Matthew T. Campbell, Petros Grivas, Guru P. Sonpavde, Deepak Kilari, Ajjai S. Alva
Publikováno v:
CancerReferences. 128(6)
Enfortumab vedotin (EV) is a novel antibody-drug conjugate approved for advanced urothelial cancer (aUC) refractory to prior therapy. In the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study, the authors looked at the exp